BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 18812781)

  • 1. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.
    Qian CX; Bahar I; Levinger E; Rootman D
    Cornea; 2008 Oct; 27(9):1090-2. PubMed ID: 18812781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
    Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.
    Yeung SN; Lichtinger A; Kim P; Amiran MD; Slomovic AR
    Cornea; 2011 Oct; 30(10):1110-4. PubMed ID: 21673570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition.
    Chu HS; Hu FR; Yang CM; Yeh PT; Chen YM; Hou YC; Chen WL
    Cornea; 2011 Jan; 30(1):60-6. PubMed ID: 20847676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subconjunctival bevacizumab for corneal neovascularization.
    Doctor PP; Bhat PV; Foster CS
    Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs.
    Koenig Y; Bock F; Kruse FE; Stock K; Cursiefen C
    Cornea; 2012 Aug; 31(8):887-92. PubMed ID: 22362005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.
    You IC; Kang IS; Lee SH; Yoon KC
    Acta Ophthalmol; 2009 Sep; 87(6):653-8. PubMed ID: 19021596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
    Kim TI; Kim SW; Kim S; Kim T; Kim EK
    Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subconjunctival bevacizumab for corneal neovascularization.
    Erdurmus M; Totan Y
    Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1577-9. PubMed ID: 17458556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
    Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
    Curr Eye Res; 2008 Jan; 33(1):23-8. PubMed ID: 18214740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subconjunctival bevacizumab injection for corneal neovascularization.
    Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
    Cornea; 2008 Feb; 27(2):142-7. PubMed ID: 18216566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
    Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
    Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.
    Oh JY; Kim MK; Wee WR
    Cornea; 2009 Oct; 28(9):1070-3. PubMed ID: 19724199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence of corneal neovascularization associated with lipid deposition after subconjunctival injection of bevacizumab.
    Chu HS; Chen TC; Hu FR; Chen WL
    Cornea; 2013 Nov; 32(11):1446-53. PubMed ID: 24055900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Subconjunctival bevacizumab for corneal neovascularization].
    Gueudry J; Richez F; Tougeron-Brousseau B; Genevois O; Muraine M
    J Fr Ophtalmol; 2010 Nov; 33(9):630-6. PubMed ID: 21035899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subconjunctival bevacizumab for corneal neovascularization.
    Zaki AA; Farid SF
    Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
    Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
    Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.
    Lin CT; Hu FR; Kuo KT; Chen YM; Chu HS; Lin YH; Chen WL
    Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6277-85. PubMed ID: 20435600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization.
    You IC; Im SK; Lee SH; Yoon KC
    Cornea; 2011 Jan; 30(1):30-3. PubMed ID: 20861729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
    Avisar I; Weinberger D; Kremer I
    Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.